Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-12
2006-09-12
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S359000, C546S268400, C548S255000
Reexamination Certificate
active
07105548
ABSTRACT:
Triazole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl which are metabotropic glutamate receptor—subtype 5 (“mGluR5”) modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal and other diseases.
REFERENCES:
patent: 5064844 (1991-11-01), O'Mahony et al.
patent: 5284860 (1994-02-01), Ozaki et al.
Cosford Nicholas D. P.
Prasit Petpiboon
Roppe Jeffrey R.
Smith Nicholas D.
Tehrani Lida R.
Chung Susannah L.
Merck & Co. , Inc.
Rose David
Rubin David
Saeed Kamal A.
LandOfFree
Heteroaryl substituted triazole modulators of metabotropic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroaryl substituted triazole modulators of metabotropic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaryl substituted triazole modulators of metabotropic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3587405